CollPlant Biotechnologies Files November 2025 6-K Report
Ticker: CLGN · Form: 6-K · Filed: Nov 26, 2025 · CIK: 1631487
Sentiment: neutral
Topics: 6-K, reporting, foreign-private-issuer
TL;DR
CollPlant filed its Nov 2025 6-K, check the press release for updates.
AI Summary
CollPlant Biotechnologies Ltd. filed a Form 6-K on November 26, 2025, reporting on their activities for the month of November 2025. The filing includes a press release titled "Collplant Biotechnologies Reports 2025 Th". The company is incorporated in Israel and its principal executive office is located in Rehovot.
Why It Matters
This filing provides an update on CollPlant's recent activities and financial reporting, which is crucial for investors to assess the company's ongoing performance and strategic direction.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that primarily serves as an informational update and does not appear to contain significant new financial or strategic disclosures that would immediately alter risk.
Key Players & Entities
- CollPlant Biotechnologies Ltd. (company) — Registrant
- November 2025 (date) — Reporting period
- 20251126 (date) — Filing date
- Rehovot, Israel (location) — Principal executive office
FAQ
What is the specific title of the press release mentioned in the 6-K filing?
The press release is titled "Collplant Biotechnologies Reports 2025 Th".
What is the SEC file number for CollPlant Biotechnologies Ltd.?
The SEC file number is 001-38370.
Where is CollPlant Biotechnologies Ltd.'s principal executive office located?
The principal executive office is located at 4 Oppenheimer St, Weizmann Science Park, Rehovot 7670104, Israel.
Does CollPlant Biotechnologies Ltd. file annual reports under Form 20-F or Form 40-F?
CollPlant Biotechnologies Ltd. files annual reports under cover of Form 20-F.
What is the SIC code for CollPlant Biotechnologies Ltd.?
The Standard Industrial Classification (SIC) code is 3842, which corresponds to Orthopedic, Prosthetic & Surgical Appliances & Supplies.
Filing Stats: 190 words · 1 min read · ~1 pages · Grade level 14.7 · Accepted 2025-11-26 07:38:38
Filing Documents
- ea0267204-6k_collplant.htm (6-K) — 8KB
- ea026720401ex99-1_collplant.htm (EX-99.1) — 144KB
- ex99-1_001.jpg (GRAPHIC) — 7KB
- 0001213900-25-115064.txt ( ) — 164KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. COLLPLANT BIOTECHNOLOGIES LTD. Date: November 26, 2025 By: /s/ Eran Rotem Name: Eran Rotem Title: Deputy CEO and Chief Financial Officer 2